STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 3/Line 55-58	Abstract/Paragraph 2
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3/Line 61-Page 4/Line 79	Abstract/Paragraph 2-3
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 6/Line 107-Page 8/Line 157	Introduction/Paragraph 1-5
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 7/Line 141-143	Introduction/Paragraph 4
Methods				
Study design	4	Present key elements of study design early in the paper	Page 3/Line 61-64	Abstract/Paragraph 2
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 8/Line 167-170 Page 9/Line 182-183	Methods/Paragraph 1-2
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 8/Line 174-177	Methods/Paragraph 1
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A	N/A
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 8/Line 178-Page 9/Line 186	Methods/Paragraph 2
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 9/Line 184-186	Methods/Paragraph 2
Bias	9	Describe any efforts to address potential sources of bias	N/A	N/A
Study size	10	Explain how the study size was arrived at	As this study is a retrospective cohort	
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A	N/A

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 12/Line 255-269	Methods/Paragraph 8
		(b) Describe any methods used to examine subgroups and interactions	N/A	N/A
		(c) Explain how missing data were addressed	Page 16/Line 363-365	Results/Paragraph 9
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A	N/A
		(e) Describe any sensitivity analyses	N/A	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 12/Line 273-274 Page 14/Line 327	Results/Paragraph 1 and paragraph 5
		(b) Give reasons for non-participation at each stage	N/A	N/A
		(c) Consider use of a flow diagram	N/A	No cases were excluded/ineligible
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 12/Line 275-283 Page 14/Line 327-331	Results/Paragraph 1 and paragraph 5 Table 1, 4 and Supp table
		(b) Indicate number of participants with missing data for each variable of interest	Page 13/Line 279-283 Page 16/Line 368-369	Results/Paragraph 1 and 10
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	Page 14/Line 311-312 Page 15/Line 338-339	Results/Paragraph 5, 7 and 12
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	Page 14/Line 310-311 Page 15/Line 337-338	Results/Paragraph 5 and 7
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	N/A	N/A
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A	N/A
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 14/Line 312-316 Page 15/Line 339-343	Results/Paragraph 5 and 7 Table 3 and 5
		(b) Report category boundaries when continuous variables were categorized	Page 12/Line 263-264 Page 14/Line 313	Methods/Paragraph 8 Results/Paragraph 5
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	N/A
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 21/Line 497-502	Discussion/Paragraph 1
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 24/Line 576-Page 25/Line 585	Discussion/Paragraph 7

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 22/Line 503-Page 24 Line 575	Discussion/paragraph 2-6
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 25/Line 583-585	Discussion/Paragraph 7
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 26/Line 608-618	Acknowledgments/Paragraph 2

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/tlcr-24-284
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copy editing and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.